HX-044

N/A

Report date: 2025/07/16 17:46:21

Base Information

Drug NameHX-044
Drug Alias NameHX044HX-044
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsSignal-regulatory protein alpha modulators
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4Signal-regulatory protein alpha
Therapy Area/IndicationsSolid tumoursLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHanx Biopharmaceuticals Pty Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHanx Biopharmaceuticals Pty LtdHanx Biopharmaceuticals (Wuhan) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A